Riedel Thyroiditis Medication

  • Author: Chris K Guerin, MD, FACE; Chief Editor: George T Griffing, MD   more...
 
Updated: Feb 16, 2012
 

Medication Summary

As previously stated, corticosteroid therapy is the medical treatment of choice for patients with Riedel thyroiditis (RT).[17] These drugs have been found in most studies to reduce goiter size and relieve local compressive symptoms, although apparently not all patients benefit from treatment.

Tamoxifen can be used as a first-line therapy in patients with RT, or it can be employed as an alternative treatment if corticosteroid treatment fails. Levothyroxine is used to correct RT-associated hypothyroidism.[16]

Next

Corticosteroids

Class Summary

Corticosteroids have anti-inflammatory properties and cause profound and varied metabolic effects. These agents modify the body's immune response to diverse stimuli.

View full drug information

Prednisone

 

Prednisone is an immunosuppressant for the treatment of autoimmune disorders. It may decrease inflammation by reversing increased capillary permeability and suppressing polymorphonuclear leukocyte activity. The drug stabilizes lysosomal membranes and suppresses lymphocytes and antibody production.

View full drug information

Prednisolone (Pediapred, Prelone, Orapred)

 

Prednisolone may decrease inflammation by reversing increased capillary permeability and suppressing polymorphonuclear (PMN) leukocyte activity. It is a commonly used oral agent.

Previous
Next

Antineoplastic Agents

Class Summary

Tamoxifen is used to treat progressive Riedel thyroiditis (RT) that is not responsive to corticosteroids or surgical decompression, or is administered to patients with contraindications to corticosteroid therapy. It provides symptomatic improvement, as well as size reduction of the involved tissue as measured on CT scans.

Mycophenolate is an immunosuppressive therapy often used to prevent rejection after transplantation and/or in graft versus host disease. It has been used in disorders characterized by systemic fibrosis. In one study, significant improvement was noted after 90 days when used in combination with prednisone.[22]

View full drug information

Tamoxifen

 

The proposed mechanism of action for tamoxifen is not antiestrogen activity but rather the induction of transforming growth factor beta (a potent inhibitor of fibroblast proliferation).

View full drug information

Mycophenolate (Cell-Cept)

 

The proposed mechanism of action is inhibition of both T- and B- cell lymphoctye proliferation. It may also directly inhibit fibrosis, at least in animal models.[22]

Previous
Next

Thyroid Hormones

Class Summary

Thyroid hormones are used to correct hypothyroidism associated with Riedel thyroiditis (RT).

View full drug information

Levothyroxine (Levothroid, Levoxyl, Synthroid, Unithroid)

 

Levothyroxine rapidly inhibits the release of thyroid hormones via a direct effect on the thyroid gland; it also inhibits the synthesis of thyroid hormones. Iodide also appears to attenuate cyclic adenosine monophosphate (cAMP) ̶ mediated effects of TSH. In active form, levothyroxine influences the growth and maturation of tissues. It is involved in normal growth, metabolism, and development.

Previous
 
Contributor Information and Disclosures
Author

Chris K Guerin, MD, FACE  Director, Diabetes Education Services, Chief, Division of Endocrinology, Tri-City Medical Center; Assistant Clinical Professor of Medicine, University of California, San Diego School of Medicine

Chris K Guerin, MD, FACE is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians-American Society of Internal Medicine, American Diabetes Association, American Society of Hypertension, Endocrine Society, and National Lipid Association

Disclosure: Nothing to disclose.

Coauthor(s)

John Boone, MD  Consulting Staff, Department of Otolaryngology, Naval Hospital Oak Harbor

John Boone, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD  Professor of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Medical Practice Executives, American College of Physician Executives, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical Research, Endocrine Society, International Society for Clinical Densitometry, and Southern Society for Clinical Investigation

Disclosure: Nothing to disclose.

Additional Contributors

Stephanie L Lee, MD, PhD Associate Professor, Department of Medicine, Boston University School of Medicine; Director of Thyroid Health Center, Associate Chief, Section of Endocrinology, Diabetes and Nutrition, Boston Medical Center; Fellow, Association of Clinical Endocrinology

Stephanie L Lee, MD, PhD is a member of the following medical societies: American College of Endocrinology, American Thyroid Association, and Endocrine Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Kent Wehmeier, MD Professor, Department of Internal Medicine, Division of Endocrinology, Diabetes, and Metabolism, St Louis University School of Medicine

Kent Wehmeier, MD is a member of the following medical societies: American Society of Hypertension, Endocrine Society, and International Society for Clinical Densitometry

Disclosure: Nothing to disclose.

References

  1. Riedel BM. Die chronische, zur Bildung eisenharter Tumoren fuhrende Entzundung der Schilddruse. Verh Dtsch Ges Chir. 1896;25:101-5.

  2. Schwaegerle SM, Bauer TW, Esselstyn CB Jr. Riedel's thyroiditis. Am J Clin Pathol. Dec 1988;90(6):715-22. [Medline].

  3. Fatourechi MM, Hay ID, McIver B, Sebo TJ, Fatourechi V. Invasive fibrous thyroiditis (riedel thyroiditis): the mayo clinic experience, 1976-2008. Thyroid. Jul 2011;21(7):765-72. [Medline].

  4. Divatia M, Kim SA, Ro JY. IgG4-related sclerosing disease, an emerging entity: a review of a multi-system disease. Yonsei Med J. Jan 2012;53(1):15-34. [Medline]. [Full Text].

  5. Dahlgren M, Khosroshahi A, Nielsen GP, Deshpande V, Stone JH. Riedel's thyroiditis and multifocal fibrosclerosis are part of the IgG4-related systemic disease spectrum. Arthritis Care Res (Hoboken). Sep 2010;62(9):1312-8. [Medline].

  6. Oguz KK, Kiratli H, Oguz O, et al. Multifocal fibrosclerosis: a new case report and review of the literature. Eur Radiol. May 2002;12(5):1134-8. [Medline].

  7. Hennessey JV. Clinical review: Riedel's thyroiditis: a clinical review. J Clin Endocrinol Metab. Oct 2011;96(10):3031-41. [Medline].

  8. Perimenis P, Marcelli S, Leteurtre E, et al. [Riedel's thyroiditis: current aspects]. Presse Med. Jun 2008;37(6 Pt 2):1015-21. [Medline].

  9. Li Y, Nishihara E, Kakudo K. Hashimoto's thyroiditis: old concepts and new insights. Curr Opin Rheumatol. Jan 2011;23(1):102-7. [Medline].

  10. Morselli-Labate AM, Pezzilli R. Usefulness of serum IgG4 in the diagnosis and follow up of autoimmune pancreatitis: A systematic literature review and meta-analysis. J Gastroenterol Hepatol. Jan 2009;24(1):15-36. [Medline].

  11. Khosroshahi A, Stone JR, Pratt DS, Deshpande V, Stone JH. Painless jaundice with serial multi-organ dysfunction. Lancet. Apr 25 2009;373(9673):1494. [Medline].

  12. Drieskens O, Blockmans D, Van den Bruel A, et al. Riedel's thyroiditis and retroperitoneal fibrosis in multifocal fibrosclerosis: positron emission tomographic findings. Clin Nucl Med. Jun 2002;27(6):413-5. [Medline].

  13. Kotilainen P, Airas L, Kojo T, et al. Positron emission tomography as an aid in the diagnosis and follow-up of Riedel's thyroiditis. Eur J Intern Med. 2004;15:186-9.

  14. Beahrs OH, McConahey WM, Woolner LB. Invasive fibrous thyroiditis (Riedel's struma). J Clin Endocrinol Metab. Feb 1957;17(2):201-20. [Medline].

  15. Lorenz K, Gimm O, Holzhausen HJ, et al. Riedel's thyroiditis: impact and strategy of a challenging surgery. Langenbecks Arch Surg. Jul 2007;392(4):405-12. [Medline].

  16. Lo JC, Loh KC, Rubin AL, et al. Riedel's thyroiditis presenting with hypothyroidism and hypoparathyroidism: dramatic response to glucocorticoid and thyroxine therapy. Clin Endocrinol (Oxf). Jun 1998;48(6):815-8. [Medline].

  17. Vaidya B, Harris PE, Barrett P, et al. Corticosteroid therapy in Riedel's thyroiditis. Postgrad Med J. Dec 1997;73(866):817-9. [Medline].

  18. Few J, Thompson NW, Angelos P, et al. Riedel's thyroiditis: treatment with tamoxifen. Surgery. Dec 1996;120(6):993-8; discussion 998-9. [Medline].

  19. De M, Jaap A, Dempster J. Tamoxifen therapy in steroid resistant Reidel's thyroiditis. Scott Med J. Apr 2001;46(2):56-7. [Medline].

  20. Jung YJ, Schaub CR, Rhoades R, et al. A case of Riedel's thyroiditis treated with tamoxifen: another successful outcome. Endocr Pract. 2004;10(6):483-6.

  21. Pritchyk K, Newkirk K, Garlich P, et al. Tamoxifen therapy for Riedel's thyroiditis. Laryngoscope. Oct 2004;114(10):1758-60. [Medline].

  22. Levy JM, Hasney CP, Friedlander PL, Kandil E, Occhipinti EA, Kahn MJ. Combined mycophenolate mofetil and prednisone therapy in tamoxifen- and prednisone-resistant Reidel's thyroiditis. Thyroid. Jan 2010;20(1):105-7. [Medline].

  23. Khosroshahi A, Stone JH. A clinical overview of IgG4-related systemic disease. Curr Opin Rheumatol. Jan 2011;23(1):57-66. [Medline].

 
Previous
Next
 
Gross pathology of Riedel thyroiditis. The cut edge is avascular, with a characteristic white color. Image courtesy of SL Lee.
Riedel thyroiditis. The atrophic thyroid follicles are surrounded by a dense, inflammatory infiltrate composed of lymphocytes, plasma cells, and eosinophils and accompanied by dense fibrosis. The wide bands of keloid-type collagen located between the individual follicles and surrounding clusters are a common feature of this condition.
Riedel thyroiditis. This vein shows infiltration of its wall by a heavy, inflammatory infiltrate.
Riedel thyroiditis. The inflammatory infiltrate and dense, pink bands of fibrosis can obliterate thyroid follicles. Image courtesy of SL Lee.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.